MCRB Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Stats
Today's Volume	756 351
Average Volume	3.53M
Market Cap	139.60M
EPS	$0 ( 2023-11-01 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.970
ATR14	$0.0700 (6.45%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-27	Cloghessy Paula	Buy	9 418	Common Stock
2023-10-30	Cloghessy Paula	Sell	2 904	Common Stock
2023-04-27	Cloghessy Paula	Buy	18 835	Restricted Stock Units
2023-10-27	Cloghessy Paula	Sell	9 418	Restricted Stock Units
2023-10-27	Shaff Eric D.	Buy	27 838	Common Stock

INSIDER POWER
89.88
Last 96 transactions
Buy: 7 491 099 \| Sell: 164 875

Volume Correlation

Long: -0.57 (weak negative)

Short: 0.75 (moderate)

Signal:(43) Neutral

Seres Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Seres Therapeutics Inc Correlation - Currency/Commodity

-0.42
( neutral )

0.00
( neutral )

-0.85
( strong negative )

Seres Therapeutics Inc Financials

Annual	2022
Revenue:	$7.13M
Gross Profit:	$6.12M (85.91 %)
EPS:	$-2.35

Q3	2023
Revenue:	$310 000
Gross Profit:	$-209 000 (-67.42 %)
EPS:	$-0.370

Q2	2023
Revenue:	$126.47M
Gross Profit:	$124.37M (98.33 %)
EPS:	$0.360

Q1	2023
Revenue:	$-522 000
Gross Profit:	$-4.13M (791.00 %)
EPS:	$-0.570

Seres Therapeutics Inc

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.